-
[Illinois] Biophotonics 2012: Breast Cancer Biomarkers - From Serendipity to Rational Discovery
25 May 2012 | | Contributor(s):: Partha Ray
…
-
[Illinois] Biophotonics 2012: Chemical Imaging for Cancer Pathology
05 Jun 2012 | | Contributor(s):: Michael Walsh
…
-
[Illinois] Cancer Basics
01 Aug 2014 | | Contributor(s):: Ann Nardulli
-
[Illinois] Cancer Community Symposium 2012
16 May 2013 |
Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancementSymposium PremiseThis on-campus research symposium aims to bring together members of campus and the surrounding community to foster interdisciplinary discussions on cancer...
-
[Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)
09 May 2012 | | Contributor(s):: Jennifer Stone
Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against...
-
[Illinois] Cancer Community Symposium 2012: An Integrated Approach to Cancer Research
09 May 2012 | | Contributor(s):: John F. McDonald
The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with analytical chemistry, computer science/machine learning and material science/nanotechnology to develop...
-
[Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling
09 May 2012 | | Contributor(s):: Elvira de Mejia
Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB SignalingLunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon cancer...
-
[Illinois] Cancer Community Symposium 2012: Chemical Imaging for Histopathology: An Emerging Route for Molecular and Structural Analysis of Tissues
09 May 2012 | | Contributor(s):: Michael Walsh
Mid-Infrared (IR) spectroscopic imaging is an emerging approach to derive chemical images from tissues based on their inherent biochemistry. Histologic diagnosis is the gold standard for evaluating the presence and severity of most diseases. Current histopathological techniques use of panel of...
-
[Illinois] Cancer Community Symposium 2012: Closing Address and Awards
09 May 2012 | | Contributor(s):: Rohit Bhargava
Jaeyun Sung announces the awards from the poster sessions. Dr. Rohit Bhargava provides the audience with reflections on the conference and thoughts going forward.Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancementSymposium...
-
[Illinois] Cancer Community Symposium 2012: Imaging Estrogen Receptors and Estrogen-Receptor Function in Breast Cancer by Positron Emission Tomography (PET): Improved Selection of Patients for Benefit from Endocrine Therapies
09 May 2012 | | Contributor(s):: John A. Katzenellenbogen
The growth of many breast cancers is regulated by estrogens, and these cancers can be treated effectively with endocrine therapies (ET). Identifying patients who will benefit from ET, however, continues to be challenging. Measurement of estrogen receptor (ER) levels in tumor biopsy samples using...
-
[Illinois] Cancer Community Symposium 2012: Materials Science vs. Metastasis
09 May 2012 | | Contributor(s):: Daniel A. Heller
Metastasis, the spread of cancer cells from a primary tumor to seed secondary tumors in distant sites, is one of the greatest challenges in cancer treatment today. For many patients, by the time cancer is detected, metastasis has already occurred. Over 80% of patients diagnosed with lung cancer,...
-
[Illinois] Cancer Community Symposium 2012: Micro-western Arrays for Identification of Novel Mechanisms Underlying Resistance of Cancer Cells to Chemotherapeutic Agents
09 May 2012 | | Contributor(s):: Richard B. Jones
A fundamental goal in cancer treatment is the delivery of therapeutics in a manner that takes into consideration genetic differences between individuals. Genome-wide association analyses have discovered many DNA variants that influence complex phenotypes such as response to anti-cancer...
-
[Illinois] Cancer Community Symposium 2012: Panel Discussion
09 May 2012 |
Please join us for a panel discussion on the social impact of cancer and how it affects patients, providers, clinicians, and researchers alike. We are fortunate to feature Leslie Hammersmith (moderator), Jennifer Smith, and Patience Anders from the local Young Survival Coalition, as well as an...
-
[Illinois] Cancer Community Symposium 2012: Speaking Up: The Patient Push for Accelerating Progress in Cancer Research
09 May 2012 | | Contributor(s):: Leslie Hammersmith
Medical research empowers us to fight cancer, and advocacy empowers us to ensure that it addresses the needs of people affected by cancer. Advocacy helps us get through our cancer experiences, stand up for all people affected by cancer and gain a feeling of control over our own healthcare. Young...
-
[Illinois] Cancer Community Symposium 2012: T Cell Receptors For Potential Cancer Immunotherapy Applications: Single Chain T Cell Receptors Circumvent Mispairing with Endogenous TCR and Mediate T Cell Activity
09 May 2012 | | Contributor(s):: David H. Aggen
To improve the immune response to cancer, gene therapy with tumor-specific T cell-receptors (TCRs) provides an attractive approach to effectively arm patients T cells for tumor cell destruction. A high-affinity TCR specific for an antigenic peptide-major histocompatibility complex (pepMHC) can be...
-
[Illinois] Cancer Community Symposium 2012: The Inhibitory Effects of the Antifibrotic Drug Halofuginone on Uterine Leiomyoma Smooth Muscle Cells
09 May 2012 | | Contributor(s):: Faezeh Koohestani
Uterine leiomyomas are the most prevalent benign tumors of the reproductive tract in women. Available treatments for leiomyomas are limited to surgical procedures or hormonal therapy, which are costly and have significant side effects. In an effort to develop alternative therapeutic strategies,...
-
[Illinois] Cancer Community Symposium 2012: The Man with the Crateriform Lesion: Advanced Squamous Cell Carcinoma
09 May 2012 | | Contributor(s):: Joseph Brancheck
Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer in the United States and accounts for 20 percent of non-melanoma skin cancers; in addition, it is the second most common cancer overall in Caucasians. Due to an aging population and increasing sun exposure, the...
-
[Illinois] Cancer Community Symposium 2012: Understanding and Targeting Transcription in Hematological Malignancies
09 May 2012 | | Contributor(s):: Jonathan D. Licht
Abnormalities in the epigenetic regulation of chromatin structure and function can lead to aberrant gene expression and cancer development. Epigenetic regulators can be affected by chromosomal rearrangement, point mutations, deletions and amplifications in cancer. The result may be changes in the...
-
[Illinois] Chemical and Biological Detection for Diagnostic, Food Safety, and Drug Safety using the Internal Sensing Capabilities of Mobile Devices
20 Jul 2016 | | Contributor(s):: Brian Cunningham
The overall objective of the 2015 BioNanotechnology Summer Institute is to enhance the ability to address challenges in Cancer Nanotechnology and Mechanobiology, offering expertise from interdisciplinary faculty in biology, engineering, materials science, and nanotechnology, through a combination...
-
[Illinois] CMMB IGERT & M-CNTC Annual Symposium: Program Overview
06 Jun 2013 | | Contributor(s):: Taher A. Saif
The second annual CMMB IGERT PI and Trainee Meeting was held on August 31, 2011. Dr. Saif walks through the goals and current status of the programs, and introduces the students involved.